Spyre Therapeutics, Inc. (SYRE) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $74.70: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 16%; Elevated put/call ratio: 2.42; Below-average business quality. (Note: Risk dimension 1.1/10 and A.R:R 1.1:1 are different metrics that happen to read the same number here.)
Spyre Therapeutics is a clinical-stage biotech developing long-acting antibodies for inflammatory bowel disease and rheumatic diseases, with four Phase 2 programs: SPY001 (anti-α4β7 for IBD), SPY002 (anti-TL1A for IBD), SPY003 (anti-IL-23 for IBD), and SPY072 (anti-TL1A for... Read more
Sell if holding. Engine safety override at $74.70: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 16%; Elevated put/call ratio: 2.42; Below-average business quality. (Note: Risk dimension 1.1/10 and A.R:R 1.1:1 are different metrics that happen to read the same number here.) Chart setup: RSI 55 mid-range, Bollinger mid-band. Score 4.7/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 55d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-11Recent Developments — Spyre Therapeutics, Inc.
Latest news
- NEWS Spyre Therapeutics Announces 12-Week Induction Data From Part A Of Phase 2 SKYLINE Study Of SPY002 To Treat Active Ulcer — benzinga Jun 15, 2026 positive
- NEWS CrowdStrike To Surge Nearly 25%? Here Are 10 Notable Analyst Calls From Thursday — benzinga Jun 4, 2026 neutral
- NEWS Deutsche Bank Maintains Buy on Spyre Therapeutics, Raises Price Target to $115 — benzinga Jun 4, 2026 positive
- NEWS Navitas Semiconductor, Abivax, MiniMed And Other Big Stocks Moving Higher On Wednesday — benzinga Jun 3, 2026 positive
- NEWS Spyre Therapeutics Completes Enrollment For All Sub-Studies In SKYWAY Basket Trial Of SPY072 In Rheumatic Diseases — benzinga Jun 3, 2026 positive
Generated 2026-06-15T18:11:47Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierWuXi Biologics10-K Item 1: 'The WuXi Biologics MSA governs certain development activities and Good Manufacturing Practice (“GMP”) manufacturing and testing for the SPY001, SPY002, and SPY003 programs'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Volatile — 5.7% daily ATR makes tight stops impractical. Position-size conservatively.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $74.70: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 16%; Elevated put/call ratio: 2.42; Below-average business quality. (Note: Risk dimension 1.1/10 and A.R:R 1.1:1 are different metrics that happen to read the same number here.) Chart setup: RSI 55 mid-range, Bollinger mid-band. Prior stop was $69.82. Score 4.7/10, moderate confidence.
Take-profit target: $86.46 (+15.2% upside). Prior stop was $69.82. Stop-loss: $69.82.
Concentration risk — Supplier: WuXi Biologics; Quality below floor (1.2 < 4.0).
Spyre Therapeutics, Inc. trades at a P/E of N/A (forward -25.2). TrendMatrix value score: 7.5/10. Verdict: Sell.
23 analysts cover SYRE with a consensus score of 4.5/5. Average price target: $96.
What does Spyre Therapeutics, Inc. do?Spyre Therapeutics is a clinical-stage biotech developing long-acting antibodies for inflammatory bowel disease and...
Spyre Therapeutics is a clinical-stage biotech developing long-acting antibodies for inflammatory bowel disease and rheumatic diseases, with four Phase 2 programs: SPY001 (anti-α4β7 for IBD), SPY002 (anti-TL1A for IBD), SPY003 (anti-IL-23 for IBD), and SPY072 (anti-TL1A for RA/PsA/axSpA). As of December 31, 2025, Spyre had $756.5 million in cash and no approved products generating revenue.